TPST · Tempest Therapeutics
The AI's read
The licensed platform gives Tempest another treatment approach to develop, and access to up to $50 million could support that work. The company also completed a private placement, but did not report its size or detailed trial results. Its $0.9 million cash balance is a serious constraint, so the pipeline and funding news do not point clearly in one direction.